Ost-müük Pieris Pharmaceuticals, Inc. - PIRS CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Kauplemistingimused
| Hinnavahe | 0.06 | ||||||||
|
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.025457% | ||||||||
|
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.003235% | ||||||||
| Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
| Min kauplemise kogus | 1 | ||||||||
| Valuuta | USD | ||||||||
| Tagatis | 20% | ||||||||
| Aktsiabörs | United States of America | ||||||||
| Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Pieris Pharmaceuticals Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Võtmestatistika
| Eelmine sulgemine* | 0.79 |
| Avatud* | 0.8 |
| Aastane muutus* | -52.1% |
| Päeva ulatus* | 0.72 - 0.85 |
| 52 nädala ulatus | 0.72-2.12 |
| Keskmine maht (10 päeva) | 743.53K |
| Keskmine maht (3 kuud) | 13.81M |
| Turukapitalisatsioon | 61.51M |
| P/E suhtarv | -100.00K |
| Ringluses olevad aktsiad | 82.02M |
| Tulu | 16.85M |
| EPS | -0.56 |
| Dividendid (% kasumist) | N/A |
| Beeta | 1.08 |
| Järgmine tuluaruande kuupäev | Aug 2, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
|---|---|---|---|---|---|---|
| May 26, 2023 | 0.72 | -0.08 | -10.00% | 0.80 | 0.85 | 0.72 |
| May 25, 2023 | 0.79 | -0.04 | -4.82% | 0.83 | 0.84 | 0.79 |
| May 24, 2023 | 0.85 | -0.02 | -2.30% | 0.87 | 0.88 | 0.84 |
| May 23, 2023 | 0.89 | -0.03 | -3.26% | 0.92 | 0.92 | 0.86 |
| May 22, 2023 | 0.84 | 0.02 | 2.44% | 0.82 | 0.84 | 0.77 |
| May 19, 2023 | 0.79 | -0.07 | -8.14% | 0.86 | 0.87 | 0.78 |
| May 18, 2023 | 0.83 | 0.02 | 2.47% | 0.81 | 0.94 | 0.79 |
| May 17, 2023 | 0.76 | 0.00 | 0.00% | 0.76 | 0.79 | 0.74 |
| May 16, 2023 | 0.77 | -0.05 | -6.10% | 0.82 | 0.82 | 0.77 |
| May 15, 2023 | 0.83 | 0.00 | 0.00% | 0.83 | 0.85 | 0.78 |
| May 12, 2023 | 0.84 | -0.08 | -8.70% | 0.92 | 0.92 | 0.82 |
| May 11, 2023 | 0.93 | 0.12 | 14.81% | 0.81 | 0.96 | 0.76 |
| May 10, 2023 | 0.84 | 0.06 | 7.69% | 0.78 | 0.84 | 0.75 |
| May 9, 2023 | 0.82 | 0.02 | 2.50% | 0.80 | 0.82 | 0.73 |
| May 8, 2023 | 0.80 | -0.02 | -2.44% | 0.82 | 0.84 | 0.79 |
| May 5, 2023 | 0.83 | 0.05 | 6.41% | 0.78 | 0.85 | 0.78 |
| May 4, 2023 | 0.77 | -0.03 | -3.75% | 0.80 | 0.84 | 0.74 |
| May 3, 2023 | 0.79 | 0.03 | 3.95% | 0.76 | 0.80 | 0.72 |
| May 2, 2023 | 0.74 | 0.03 | 4.23% | 0.71 | 0.74 | 0.70 |
| May 1, 2023 | 0.73 | 0.00 | 0.00% | 0.73 | 0.74 | 0.70 |
Pieris Pharmaceuticals, Inc. Events
| Kellaaeg (UTC) (UTC) | Riik | Sündmus |
|---|---|---|
| Wednesday, June 21, 2023 | ||
| Kellaaeg (UTC) (UTC) 12:00 | Riik US
| Sündmus Pieris Pharmaceuticals Inc Annual Shareholders Meeting Pieris Pharmaceuticals Inc Annual Shareholders MeetingForecast -Previous - |
| Thursday, June 22, 2023 | ||
| Kellaaeg (UTC) (UTC) 12:00 | Riik US
| Sündmus Pieris Pharmaceuticals Inc Annual Shareholders Meeting Pieris Pharmaceuticals Inc Annual Shareholders MeetingForecast -Previous - |
| Wednesday, August 2, 2023 | ||
| Kellaaeg (UTC) (UTC) 12:30 | Riik US
| Sündmus Q2 2023 Pieris Pharmaceuticals Inc Earnings Release Q2 2023 Pieris Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
| Tuesday, October 31, 2023 | ||
| Kellaaeg (UTC) (UTC) 12:30 | Riik US
| Sündmus Q3 2023 Pieris Pharmaceuticals Inc Earnings Release Q3 2023 Pieris Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Aastas
- Kvartalis
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Kogutulu | 25.902 | 31.418 | 29.323 | 46.279 | 29.101 |
| Tulu | 25.902 | 31.418 | 29.323 | 46.279 | 29.101 |
| Kogu tegevuskulu | 61.203 | 79.564 | 63.244 | 73.436 | 59.932 |
| Müük/Üldine/admin kulud, kokku | 16.394 | 16.593 | 16.713 | 18.44 | 18.442 |
| Uuringud ja arendus | 52.982 | 66.656 | 46.531 | 54.996 | 41.49 |
| Tulud majandustegevusest | -35.301 | -48.146 | -33.921 | -27.157 | -30.831 |
| Intressitulud (kulu), muud tulud, neto | 0.721 | 0.004 | 0.511 | 1.714 | 1.962 |
| Muud, neto | 1.303 | 2.404 | -3.656 | -0.026 | 1.803 |
| Netotulu enne makse | -33.277 | -45.738 | -37.066 | -25.469 | -27.066 |
| Netotulu pärast makse | -33.277 | -45.738 | -37.23 | -25.469 | -26.754 |
| Netotulu enne erikulusid | -33.277 | -45.738 | -37.23 | -25.469 | -26.754 |
| Netotulu | -33.277 | -45.738 | -37.23 | -25.469 | -26.754 |
| Total Adjustments to Net Income | -2.83 | ||||
| Arvestatav tulu, v a erikulud | -33.277 | -45.738 | -37.23 | -28.299 | -26.754 |
| Arvestatav tulu, koos erikuludega | -33.277 | -45.738 | -37.23 | -28.299 | -26.754 |
| Jaotamisele kuuluv netotulu | -33.277 | -45.738 | -37.23 | -28.299 | -26.754 |
| Keskmine jaotamisele kuuluv aktsia kohta | 74.172 | 64.547 | 54.481 | 50.625 | 53.081 |
| Jaotatav EPS, v a erakorralised kulud | -0.44865 | -0.7086 | -0.68336 | -0.55899 | -0.50402 |
| Jaotamisele kuuluv normaal-EPS | -0.55884 | -0.76569 | -0.68336 | -0.55899 | -0.50402 |
| Erakorralised kulud kokku | |||||
| Ootamatud kulutused (tulu) | -8.173 | -3.685 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Kogutulu | 1.936 | 5.846 | 5.37 | 3.698 | 10.988 |
| Tulu | 1.936 | 5.846 | 5.37 | 3.698 | 10.988 |
| Kogu tegevuskulu | 15.419 | 13.974 | 16.07 | 14.844 | 16.315 |
| Müük/Üldine/admin kulud, kokku | 4.023 | 3.985 | 3.949 | 4.081 | 4.379 |
| Uuringud ja arendus | 13.424 | 13.38 | 13.589 | 11.947 | 14.066 |
| Tulud majandustegevusest | -13.483 | -8.128 | -10.7 | -11.146 | -5.327 |
| Intressitulud (kulu), muud tulud, neto | 0.357 | 0.351 | 0.241 | 0.132 | -0.003 |
| Muud, neto | -0.057 | -0.325 | 0.723 | 0.676 | 0.229 |
| Netotulu enne makse | -13.183 | -8.102 | -9.736 | -10.338 | -5.101 |
| Netotulu pärast makse | -13.183 | -8.102 | -9.736 | -10.338 | -5.101 |
| Netotulu enne erikulusid | -13.183 | -8.102 | -9.736 | -10.338 | -5.101 |
| Netotulu | -13.183 | -8.102 | -9.736 | -10.338 | -5.101 |
| Arvestatav tulu, v a erikulud | -13.183 | -8.102 | -9.736 | -10.338 | -5.101 |
| Arvestatav tulu, koos erikuludega | -13.183 | -8.102 | -9.736 | -10.338 | -5.101 |
| Jaotamisele kuuluv netotulu | -13.183 | -8.102 | -9.736 | -10.338 | -5.101 |
| Keskmine jaotamisele kuuluv aktsia kohta | 74.519 | 74.448 | 74.397 | 74.125 | 73.711 |
| Jaotatav EPS, v a erakorralised kulud | -0.17691 | -0.10883 | -0.13087 | -0.13947 | -0.0692 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Jaotamisele kuuluv normaal-EPS | -0.20412 | -0.15438 | -0.1506 | -0.15544 | -0.0981 |
| Ootamatud kulutused (tulu) | -2.028 | -3.391 | -1.468 | -1.184 | -2.13 |
- Aastas
- Kvartalis
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 73.424 | 127.625 | 75.721 | 115.013 | 135.382 |
| Raha ja lühiajalised investeeringud | 59.169 | 117.764 | 70.436 | 104.154 | 128.107 |
| Raha ja ekvivalendid | 38.635 | 117.764 | 70.436 | 62.26 | 74.867 |
| Laekumata arved, neto | 5.81 | 3.313 | 1.706 | 6.787 | 2.701 |
| Accounts Receivable - Trade, Net | 5.81 | 3.313 | 1.706 | 6.787 | 2.701 |
| Prepaid Expenses | 8.445 | 6.548 | 3.579 | 4.072 | 4.574 |
| Total Assets | 95.49 | 153.56 | 105.01 | 141.097 | 141.341 |
| Property/Plant/Equipment, Total - Net | 20.697 | 23.031 | 25.98 | 22.938 | 5.049 |
| Property/Plant/Equipment, Total - Gross | 30.344 | 30.748 | 31.795 | 26.505 | 8.415 |
| Accumulated Depreciation, Total | -9.647 | -7.717 | -5.815 | -3.567 | -3.366 |
| Other Long Term Assets, Total | 1.369 | 2.904 | 3.309 | 3.146 | 0.91 |
| Total Current Liabilities | 36.583 | 50.561 | 22.145 | 27.003 | 48.076 |
| Accounts Payable | 4.154 | 8.609 | 1.787 | 5.803 | 3.35 |
| Accrued Expenses | 11.122 | 14.833 | 7.496 | 9.486 | 8.169 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 21.307 | 27.119 | 12.862 | 11.714 | 36.557 |
| Total Liabilities | 67.561 | 102.805 | 73.983 | 89.745 | 101.406 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 30.978 | 52.244 | 51.838 | 62.742 | 53.33 |
| Total Equity | 27.929 | 50.755 | 31.027 | 51.352 | 39.935 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.074 | 0.072 | 0.056 | 0.055 | 0.054 |
| Additional Paid-In Capital | 318.53 | 306.998 | 242.672 | 227.468 | 189.929 |
| Retained Earnings (Accumulated Deficit) | -290.421 | -257.144 | -211.406 | -174.176 | -147.066 |
| Other Equity, Total | -0.254 | 0.829 | -0.295 | -1.995 | -2.982 |
| Total Liabilities & Shareholders’ Equity | 95.49 | 153.56 | 105.01 | 141.097 | 141.341 |
| Total Common Shares Outstanding | 74.5191 | 72.2227 | 56.0028 | 55.2124 | 54.1512 |
| Lühiajalised investeeringud | 20.534 | 0 | 41.894 | 53.24 | |
| Long Term Investments | 0 | ||||
| Total Preferred Shares Outstanding | 0.00762 | 0.00762 | 0.01443 | 0.01143 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 60.505 | 73.424 | 78.56 | 90.904 | 111.749 |
| Raha ja lühiajalised investeeringud | 48.379 | 59.169 | 69.823 | 80.936 | 100.268 |
| Raha ja ekvivalendid | 39.742 | 38.635 | 48.423 | 54.257 | 83.737 |
| Laekumata arved, neto | 1.055 | 5.81 | 0.829 | 1.264 | 1.644 |
| Accounts Receivable - Trade, Net | 1.055 | 5.81 | 0.829 | 1.264 | 1.644 |
| Prepaid Expenses | 11.071 | 8.445 | 7.908 | 8.704 | 9.837 |
| Total Assets | 82.258 | 95.49 | 99.163 | 114.309 | 137.115 |
| Property/Plant/Equipment, Total - Net | 20.502 | 20.697 | 19.296 | 21.047 | 22.693 |
| Property/Plant/Equipment, Total - Gross | 30.476 | 30.344 | 27.615 | 29.292 | 30.87 |
| Accumulated Depreciation, Total | -9.974 | -9.647 | -8.319 | -8.245 | -8.177 |
| Other Long Term Assets, Total | 1.251 | 1.369 | 1.307 | 2.358 | 2.673 |
| Total Current Liabilities | 42.875 | 36.583 | 33.521 | 35.546 | 39.484 |
| Accounts Payable | 5.833 | 4.154 | 3.641 | 1.898 | 4.496 |
| Accrued Expenses | 9.764 | 11.122 | 10.801 | 10.175 | 11.858 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 27.278 | 21.307 | 19.079 | 23.473 | 23.13 |
| Total Liabilities | 66.8 | 67.561 | 63.396 | 69.944 | 83.665 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 23.925 | 30.978 | 29.875 | 34.398 | 44.181 |
| Total Equity | 15.458 | 27.929 | 35.767 | 44.365 | 53.45 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.074 | 0.074 | 0.074 | 0.074 | 0.074 |
| Additional Paid-In Capital | 319.414 | 318.53 | 317.488 | 316.249 | 314.668 |
| Retained Earnings (Accumulated Deficit) | -303.604 | -290.421 | -282.319 | -272.583 | -262.245 |
| Other Equity, Total | -0.426 | -0.254 | 0.524 | 0.625 | 0.953 |
| Total Liabilities & Shareholders’ Equity | 82.258 | 95.49 | 99.163 | 114.309 | 137.115 |
| Total Common Shares Outstanding | 74.5191 | 74.5191 | 74.4062 | 74.2576 | 74.0979 |
| Total Preferred Shares Outstanding | 0.00762 | 0.00762 | 0.00762 | 0.00762 | 0.00762 |
| Lühiajalised investeeringud | 8.637 | 20.534 | 21.4 | 26.679 | 16.531 |
- Aastas
- Kvartalis
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Netotulu/algväärtus | -33.277 | -45.738 | -37.23 | -25.469 | -26.754 |
| Raha majandustegevusest | -59.932 | -7.66 | -45.896 | -52.467 | -1.066 |
| Raha majandustegevusest | 2.77 | 2.459 | 2.311 | 0.632 | 0.57 |
| Mittelikviidsed varad | 3.945 | 5.094 | 5.236 | 4.491 | 3.389 |
| Cash Taxes Paid | 0 | 0.908 | |||
| Makstud intressid | |||||
| Muutused tööjõus | -33.37 | 30.525 | -16.377 | -32.121 | 21.893 |
| Tulu investeeringutelt | -21.236 | -0.949 | 39.212 | 9.838 | -8.875 |
| Kapitalikulutused | -1.041 | -0.949 | -2.726 | -2.462 | -1.698 |
| Muud rahavood investeeringutelt, kokku | -20.195 | 0 | 41.938 | 12.3 | -7.177 |
| Rahavood investeeringutelt | 7.214 | 59.127 | 10.115 | 32.166 | 48.511 |
| Aktsiate emiteerimine (tagasiost), neto | 7.017 | 58.962 | 9.915 | 31.797 | 48.511 |
| Muutused valuutakursside kõikumisest | -5.175 | -3.19 | 4.745 | -2.144 | -1.581 |
| Rahaline kogumuutus | -79.129 | 47.328 | 8.176 | -12.607 | 36.989 |
| Deferred Taxes | 0 | 0.164 | 0 | -0.164 | |
| Rahavoogudesse investeerimine | 0.197 | 0.165 | 0.2 | 0.369 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -13.183 | -33.277 | -25.175 | -15.439 | -5.101 |
| Cash From Operating Activities | -10.996 | -59.932 | -46.999 | -38.221 | -22.643 |
| Cash From Operating Activities | 0.605 | 2.77 | 2.195 | 1.428 | 0.845 |
| Non-Cash Items | 0.975 | 3.945 | 3.37 | 2.728 | 1.264 |
| Changes in Working Capital | 0.607 | -33.37 | -27.389 | -26.938 | -19.651 |
| Cash From Investing Activities | 11.903 | -21.236 | -22.343 | -27.813 | -16.948 |
| Capital Expenditures | -0.048 | -1.041 | -1.052 | -1.018 | -0.389 |
| Other Investing Cash Flow Items, Total | 11.951 | -20.195 | -21.291 | -26.795 | -16.559 |
| Cash From Financing Activities | 0 | 7.214 | 7.121 | 6.839 | 6.558 |
| Issuance (Retirement) of Stock, Net | 0 | 7.017 | 7.017 | 6.735 | 6.558 |
| Foreign Exchange Effects | 0.2 | -5.175 | -7.12 | -4.312 | -0.994 |
| Net Change in Cash | 1.107 | -79.129 | -69.341 | -63.507 | -34.027 |
| Financing Cash Flow Items | 0.197 | 0.104 | 0.104 | ||
| Deferred Taxes |
| Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
|---|---|---|---|---|---|---|
| BVF Partners L.P. | Hedge Fund | 25.1281 | 20609863 | 15529543 | 2023-05-11 | LOW |
| Lynx1 Capital Advisors LLC | Investment Advisor | 8.6172 | 7067718 | 1439133 | 2023-03-31 | |
| Aquilo Capital Management, LLC | Investment Advisor/Hedge Fund | 5.551 | 4552876 | 0 | 2023-03-31 | |
| Soleus Capital Management, L.P. | Hedge Fund | 5.0413 | 4134868 | 134868 | 2023-03-31 | HIGH |
| Seagen Inc | Corporation | 4.5187 | 3706174 | 0 | 2022-12-31 | |
| AstraZeneca PLC | Corporation | 4.37 | 3584230 | 0 | 2022-12-31 | LOW |
| Pontifax Ltd. | Venture Capital | 4.3544 | 3571428 | 0 | 2021-12-31 | LOW |
| Marshall Wace LLP | Investment Advisor/Hedge Fund | 2.7632 | 2266350 | -125686 | 2023-03-31 | HIGH |
| Citadel Advisors LLC | Hedge Fund | 2.4383 | 1999907 | -46254 | 2023-03-31 | HIGH |
| Medical Strategy GmbH | Investment Advisor | 1.9744 | 1619387 | 52729 | 2023-01-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.4366 | 1178283 | -114163 | 2023-03-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 1.2626 | 1035540 | -29441 | 2023-03-31 | LOW |
| Platinum Asset Management | Investment Advisor/Hedge Fund | 1.1888 | 975012 | -245786 | 2023-03-31 | LOW |
| Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.769 | 630690 | -251144 | 2023-03-31 | MED |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7681 | 629965 | 0 | 2023-03-31 | LOW |
| BMO Capital Markets (US) | Research Firm | 0.5873 | 481727 | 481727 | 2022-12-31 | MED |
| Walleye Capital LLC | Hedge Fund | 0.5839 | 478935 | 478935 | 2023-03-31 | HIGH |
| Renaissance Technologies LLC | Hedge Fund | 0.4699 | 385391 | -301600 | 2023-03-31 | HIGH |
| Cutter & Company, Inc. | Investment Advisor | 0.4602 | 377479 | -1000 | 2023-03-31 | LOW |
| Candriam Luxembourg S.A. | Investment Advisor | 0.429 | 351834 | -245000 | 2023-03-31 | HIGH |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group530K+
Kauplejad
87K+
Igakuiste aktiivsete klientide arv
$46M+
Igakuine investeerimise maht
$31M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
Kauplemise vahendustasu
0
- 1:1
Finantsvõimendus
1:1
- 20
- 100
- 500
- 1000
- 10000
Investeering
Tehingu suurus (võimendus x investeering):
Avamishind
Close
Lühike Pikk
Pieris Pharmaceuticals, Inc. Company profile
Ettevõttest Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc. on kliinilise faasi biotehnoloogiaettevõte, mis avastab ja arendab antikaliinil põhinevaid ravimeid, mis on suunatud valideeritud haigusradadele. Ettevõtte juhtiv hingamisteede antikaliinil põhinev ravimikandidaat PRS-060/AZD1402, mis antagoniseerib IL-4R alfa, inhibeerides seeläbi IL-4 ja IL-13, kaks tsütokiini, väikesed valgud, mis vahendavad rakkude vahelist signalisatsiooni inimkehas ja on teadaolevalt põletikukaskadi vahendajad, mis põhjustavad astma ja teiste põletikuliste haiguste patogeneesi. IO Anticalinil põhinev juhtiv ravimikandidaat, cinrebafusp alfa, mis on kavandatud immuunretseptori 4-1BB ja kasvaja sihtmärgi HER2 vastu. Cinrebafusp alfa on HER2-le suunatud antikeha variandi geneetiline fusioon 4-1BB-le spetsiifilise Anticalin-valguga.
| Industry: | Bio Therapeutic Drugs |
225 Franklin Street
26Th Floor
BOSTON
MASSACHUSETTS 02110
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 530,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com